Kiadis Pharma launch­es a pri­vate place­ment of approx­i­mate­ly 2.25 mil­lion new shares

Amsterdam-Duivendrecht, The Netherlands, October 9, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive prod­ucts to make bone mar­row trans­plan­ta­tions safer and more effec­tive for patients suf­fer­ing from blood can­cers and inher­it­ed blood dis­or­ders, today announces the launch of an undoc­u­ment­ed pri­vate place­ment of approx­i­mate­ly 2.25 mil­lion new shares to insti­tu­tion­al investors, rep­re­sent­ing approx­i­mate­ly 15.0% of the Company’s cur­rent issued share cap­i­tal (the “Placing”). The Company retains the option to increase the num­ber of shares to be sold. Kiadis Pharma intends to use the net pro­ceeds of the Placing to:
advance the Phase III inter­na­tion­al, ran­dom­ized, con­trolled, mul­ti­cen­tre clin­i­cal tri­al for ATIR101TM in the United States, Canada and Europe;
– secure addi­tion­al man­u­fac­tur­ing capac­i­ty at ven­dors and lease its own com­mer­cial man­u­fac­tur­ing facil­i­ty;
– pre­pare Kiadis Pharma for launch of ATIR101TM in the EU in 2019 by invest­ing in med­ical affairs, mar­ket access prepa­ra­tion and re-imburse­ment dis­cus­sions;
– pur­sue ATIR201 and a new study com­bin­ing ATIR101TM with the Baltimore pro­to­col and/or anoth­er T-cell deplet­ed hematopoi­et­ic stem cell trans­plan­ta­tion;
– expand the orga­ni­za­tion to accom­mo­date the increased num­ber of activ­i­ties;
– apply funds for debt repay­ment, cap­i­tal expen­di­ture, gen­er­al and admin­is­tra­tive expens­es, gen­er­al cor­po­rate pur­pos­es in line with Kiadis Pharma’s strat­e­gy and oth­er work­ing cap­i­tal needs.
The new shares will be placed with insti­tu­tion­al investors through an accel­er­at­ed book­build­ing process and the sub­scrip­tion price and the num­ber of shares to be issued in the Placing will be deter­mined through this process. The book­build­ing peri­od for the Placing will com­mence today with imme­di­ate effect and will close at short notice.
In rela­tion to the Placing, the Company has, sub­ject to cus­tom­ary exemp­tions, agreed to a lock-up under­tak­ing for a peri­od of 90 cal­en­dar days after the set­tle­ment date on future share issuances. In addi­tion, and also sub­ject to cus­tom­ary exemp­tions, the two largest share­hold­ers of the Company (funds rep­re­sent­ed by and/or affil­i­at­ed with Life Sciences Partners and Draper Esprit, togeth­er rep­re­sent­ing 51.0% of the share cap­i­tal of the Company) as well as all mem­bers of the Company’s Management Board and Supervisory Board have agreed to a lock-up under­tak­ing for a peri­od of 90 cal­en­dar days after the set­tle­ment date on future share dis­pos­als. Kreos Capital has agreed to a lock-up under­tak­ing for a peri­od of 90 cal­en­dar days after the set­tle­ment date with respect to the war­rants that were issued by the Company to Kreos Capital on 17 August 2017.
The Company will announce the final num­ber of new shares placed and the sub­scrip­tion price in the Placing in a sub­se­quent press release expect­ed to be pub­lished before the begin­ning of trad­ing on Euronext Amsterdam and Brussels on Tuesday 10 October 2017.
Jefferies International Limited is act­ing as Sole Bookrunner and Canaccord Genuity Limited and Oppenheimer & Co. Inc. are act­ing as Lead Managers in con­nec­tion with the Placing. Chardan and Saola Healthcare Partners are act­ing as finan­cial advi­sors to the Company.

About Kiadis Pharma
Kiadis Pharma is focused on cell-based immunother­a­py prod­ucts, as an adjunc­tive to a hap­loiden­ti­cal hematopoi­et­ic stem cell trans­plan­ta­tion (HSCT), for the treat­ment of blood can­cers and inher­it­ed blood dis­or­ders. The Company’s prod­uct can­di­dates have the poten­tial to make allo­gene­ic HSCT safer and more effec­tive for patients.
Based on the pos­i­tive results from the sin­gle dose Phase II tri­al with lead prod­uct ATIR101TM in patients with blood can­cer, the Company sub­mit­ted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in April 2017, for approval of ATIR101TM across the European Union as an adjunc­tive treat­ment in HSCT for malig­nant dis­ease. In addi­tion, Kiadis Pharma has received reg­u­la­to­ry approval in var­i­ous coun­tries to start dos­ing patients in a Phase III tri­al with ATIR101TM that will be per­formed across Europe and North America. ATIR101TM has been grant­ed Orphan Drug Designations both in the US and Europe. In September 2017 the US Food and Drug Administration (FDA) grant­ed ATIR101TM the Regenerative Medicine Advanced Therapy (RMAT) des­ig­na­tion.
The Company’s sec­ond prod­uct can­di­date, ATIR201TM, will address beta tha­lassemia, an inher­it­ed blood dis­or­der.
Kiadis Pharma was grant­ed an Advanced Therapy Medicinal Product (ATMP) cer­tifi­cate for man­u­fac­tur­ing qual­i­ty and non-clin­i­cal data by the EMA.
The Company’s shares are list­ed on Euronext Amsterdam and Euronext Brussels. Company web­site: www.kiadis.com